162 results
Page 4 of 9
8-K
EX-10.1
look6ajm78lvolf
25 Sep 20
Departure of Directors or Certain Officers
9:22am
8-K
EX-10.2
e45of 5y8qmenyy9egya
25 Sep 20
Departure of Directors or Certain Officers
9:22am
8-K
EX-10.2
7ck0caxx
31 Aug 20
Departure of Directors or Certain Officers
4:36pm
8-K
EX-10.1
quih ihjifwnq
31 Aug 20
Departure of Directors or Certain Officers
4:36pm
8-K
EX-10.3
yr25dl
31 Aug 20
Departure of Directors or Certain Officers
4:36pm
8-K
EX-99.1
uyju4t8o
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
9zqr1975bphq h4hvps
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
424B5
l7x2cos td8
5 May 20
Prospectus supplement for primary offering
5:05pm
DEFA14A
xg8k8qsafx5117
9 Apr 20
Additional proxy soliciting materials
4:11pm
8-K
EX-1.1
mxvg6r 9jm
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm
8-K
EX-99.1
y2bh0 2ggju
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm
424B5
plz201
4 Mar 20
Prospectus supplement for primary offering
4:15pm
424B5
143soht
2 Mar 20
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
0i0wjk4
2 Mar 20
Other Events
7:05am
8-K
EX-99.1
hn01k9p13wqcsqbyyi1
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am